The global general anesthesia drugs market size accounted for USD 5.60 billion in 2025 and is expected to be worth around USD 7.79 billion by 2034, registering a CAGR of 3.73% between 2025 and 2034. The North America general anesthesia drugs market size was evaluated at USD 2.00 billion in 2024 and is expected to grow at a CAGR of 3.86% during the forecast year. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: General Anesthesia Drugs Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by Drug
8.1.1. Sevoflurane
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Propofol
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Dexmedetomidine
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Remifentanil
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Desflurane
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Midazolam
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Others - (Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental, Etc.)
8.1.7.1. Market Revenue and Volume Forecast
9.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by Route of Administration
9.1.1. Intravenous
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Inhaled
9.1.2.1. Market Revenue and Volume Forecast
10.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by Application
10.1.1. Heart Surgeries
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Cancer
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. General Surgery
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Knee and Hip Replacements
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Volume Forecast
11.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by End-use
11.1.1. Hospitals
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Ambulatory Surgical Centers
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Others
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Cervical
11.1.4.1. Market Revenue and Volume Forecast
11.1.5. Malignant
11.1.5.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Drug
12.1.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.3. Market Revenue and Volume Forecast, by Application
12.1.4. Market Revenue and Volume Forecast, by End-use
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Drug
12.1.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.5.3. Market Revenue and Volume Forecast, by Application
12.1.5.4. Market Revenue and Volume Forecast, by End-use
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Drug
12.1.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.6.3. Market Revenue and Volume Forecast, by Application
12.1.6.4. Market Revenue and Volume Forecast, by End-use
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Drug
12.2.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.3. Market Revenue and Volume Forecast, by Application
12.2.4. Market Revenue and Volume Forecast, by End-use
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Drug
12.2.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.5.3. Market Revenue and Volume Forecast, by Application
12.2.5.4. Market Revenue and Volume Forecast, by End-use
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Drug
12.2.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.6.3. Market Revenue and Volume Forecast, by Application
12.2.6.4. Market Revenue and Volume Forecast, by End-use
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Drug
12.2.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.7.3. Market Revenue and Volume Forecast, by Application
12.2.7.4. Market Revenue and Volume Forecast, by End-use
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Drug
12.2.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.8.3. Market Revenue and Volume Forecast, by Application
12.2.8.4. Market Revenue and Volume Forecast, by End-use
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Drug
12.3.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.3. Market Revenue and Volume Forecast, by Application
12.3.4. Market Revenue and Volume Forecast, by End-use
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Drug
12.3.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.5.3. Market Revenue and Volume Forecast, by Application
12.3.5.4. Market Revenue and Volume Forecast, by End-use
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Drug
12.3.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.6.3. Market Revenue and Volume Forecast, by Application
12.3.6.4. Market Revenue and Volume Forecast, by End-use
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Drug
12.3.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.7.3. Market Revenue and Volume Forecast, by Application
12.3.7.4. Market Revenue and Volume Forecast, by End-use
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Drug
12.3.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.8.3. Market Revenue and Volume Forecast, by Application
12.3.8.4. Market Revenue and Volume Forecast, by End-use
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Drug
12.4.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.3. Market Revenue and Volume Forecast, by Application
12.4.4. Market Revenue and Volume Forecast, by End-use
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Drug
12.4.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.5.3. Market Revenue and Volume Forecast, by Application
12.4.5.4. Market Revenue and Volume Forecast, by End-use
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Drug
12.4.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.6.3. Market Revenue and Volume Forecast, by Application
12.4.6.4. Market Revenue and Volume Forecast, by End-use
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Drug
12.4.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.7.3. Market Revenue and Volume Forecast, by Application
12.4.7.4. Market Revenue and Volume Forecast, by End-use
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Drug
12.4.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.8.3. Market Revenue and Volume Forecast, by Application
12.4.8.4. Market Revenue and Volume Forecast, by End-use
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Drug
12.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.3. Market Revenue and Volume Forecast, by Application
12.5.4. Market Revenue and Volume Forecast, by End-use
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Drug
12.5.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.5.3. Market Revenue and Volume Forecast, by Application
12.5.5.4. Market Revenue and Volume Forecast, by End-use
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Drug
12.5.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.6.3. Market Revenue and Volume Forecast, by Application
12.5.6.4. Market Revenue and Volume Forecast, by End-use
13.1. Baxter International Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AstraZeneca
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Aspen Pharmacare Holdings Limited
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Hikama Pharmaceuticals plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Abbott Laboratories
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. AbbVie Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. B. Braun Melsungen AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Fresenius SE & Co. KgaA
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Pfizer
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Hospira Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description